Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

BACKGROUND: Patients with cognitive impairment associated with schizophrenia may benefit from treatments targeting dysfunctional glutamatergic neurotransmission. BI 409306, a potent and selective phosphodiesterase 9 inhibitor, was assessed in patients with schizophrenia using a learn-and-confirm ada...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, David, Nakagome, Kazuyuki, Cordes, Joachim, Brenner, Ronald, Gründer, Gerhard, Keefe, Richard S E, Riesenberg, Robert, Walling, David P, Daniels, Kristen, Wang, Lara, McGinniss, Jennifer, Sand, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403090/
https://www.ncbi.nlm.nih.gov/pubmed/29718385
http://dx.doi.org/10.1093/schbul/sby049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403090/
https://www.ncbi.nlm.nih.gov/pubmed/29718385
http://dx.doi.org/10.1093/schbul/sby049

Ejemplares similares